Solara Active Pharma Sciences Limited Stock Price Today (NSE: SOLARA)
Fundamental Score
Solara Active Pharma Sciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Solara Active Pharma Sciences Limited share price today is ₹711.50, down 0.60% on NSE/BSE as of 16 September 2026. Solara Active Pharma Sciences Limited (SOLARA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.42K (Cr). The 52-week high for SOLARA share price is ₹774.00 and the 52-week low is ₹422.00. The company has a Return on Equity (ROE) of -0.63% and a debt-to-equity ratio of 0.53.
Solara Active Pharma Sciences Limited Share Price Chart — NSE/BSE Historical Performance
Solara Active Pharma Sciences Limited share price chart: 36.48% return over the past month. 52-week high ₹774.00, 52-week low ₹422.00.
Solara Active Pharma Sciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹715.00 | ₹730.00 | ₹669.00 | ₹711.50 | 7.30L (Cr) | |
| ₹761.45 | ₹774.00 | ₹711.10 | ₹715.80 | 6.97L (Cr) | |
| ₹707.20 | ₹759.55 | ₹697.40 | ₹749.15 | 11.60L (Cr) | |
| ₹691.00 | ₹749.80 | ₹690.00 | ₹707.25 | 14.64L (Cr) | |
| ₹700.00 | ₹707.95 | ₹688.05 | ₹690.50 | 2.71L (Cr) | |
| ₹708.00 | ₹719.00 | ₹683.05 | ₹701.80 | 8.01L (Cr) | |
| ₹643.85 | ₹711.00 | ₹639.15 | ₹697.05 | 21.88L (Cr) | |
| ₹628.00 | ₹652.00 | ₹619.00 | ₹639.15 | 3.97L (Cr) | |
| ₹643.55 | ₹647.60 | ₹625.10 | ₹629.85 | 2.26L (Cr) | |
| ₹647.90 | ₹649.80 | ₹632.35 | ₹640.35 | 3.50L (Cr) |
Solara Active Pharma Sciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹637.50 | ₹774.00 | ₹619.00 | ₹711.50 | +11.61% | |
| ₹522.85 | ₹654.40 | ₹497.60 | ₹632.65 | +21.00% | |
| ₹576.10 | ₹601.00 | ₹471.55 | ₹513.55 | -10.86% | |
| ₹532.70 | ₹620.35 | ₹520.10 | ₹575.70 | +8.07% | |
| ₹495.80 | ₹606.40 | ₹492.20 | ₹532.70 | +7.44% | |
| ₹440.00 | ₹518.00 | ₹440.00 | ₹495.80 | +12.68% | |
| ₹452.00 | ₹479.00 | ₹422.00 | ₹425.55 | -5.85% | |
| ₹511.00 | ₹549.00 | ₹440.20 | ₹462.20 | -9.55% | |
| ₹564.95 | ₹588.05 | ₹496.05 | ₹506.20 | -10.40% | |
| ₹514.60 | ₹641.00 | ₹510.00 | ₹564.95 | +9.78% | |
| ₹603.00 | ₹647.00 | ₹502.30 | ₹514.25 | -14.72% | |
| ₹603.60 | ₹621.00 | ₹575.50 | ₹599.80 | -0.63% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Solara Active Pharma Sciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Solara Active Pharma Sciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SOLARA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (55.04%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (19.57%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Risk Factors
8 factors identified
Below-Average Return on Equity (-0.63%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.41%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-3.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (0.92x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Liquidity Concerns (Current Ratio: 0.77)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Negative Free Cash Flow (₹-64.93 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (36.57%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Solara Active Pharma Sciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Solara Active Pharma Sciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
8/100 | ₹711.50₹712 | ₹3419.47₹3419.47 | — — | -0.63%Poor -0.63% Poor | 6.41%Poor 6.41% Poor | 0.53Good 0.5 Good | — — | -3.27%Poor -3.27% Poor | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1868.80₹1869 | ₹448381.18₹448381.18 | 37.08Average 37.1 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9494.00₹9494 | ₹251591.00₹251591.00 | 86.14Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4945.50₹4946 | ₹167385.39₹167385.39 | 79.00Average 79.0 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1130.60₹1131 | ₹112833.88₹112833.88 | 25.20Average 25.2 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.70₹1372 | ₹110812.78₹110812.78 | 32.86Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1934.30₹1934 | ₹104500.56₹104500.56 | 95.47Average 95.5 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1678.90₹1679 | ₹96603.91₹96603.91 | 26.23Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2098.30₹2098 | ₹95944.77₹95944.77 | 17.34Average 17.3 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.10₹1144 | ₹95532.35₹95532.35 | 29.57Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2269.50₹2270 | ₹93730.35₹93730.35 | 45.86Average 45.9 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price448381.18 Cr
- Divi's Laboratories Limited share price251591.00 Cr
- Torrent Pharmaceuticals Limited share price167385.39 Cr
- Zydus Lifesciences Limited share price112833.88 Cr
- Cipla Limited share price110812.78 Cr
Solara Active Pharma Sciences Limited PE Ratio History
Historical price-to-earnings ratio for SOLARA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.14 | ₹564.95 | 4035.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Solara Active Pharma Sciences Limited Dividend History
Annual cash dividends paid by SOLARA — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹10.78 Cr |
| FY 2021 | ₹19.73 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Solara Active Pharma Sciences Limited Quarterly Performance
Latest quarterly metrics for SOLARA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.57%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
55.04%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-3.27%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Solara Active Pharma Sciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SOLARA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Solara Active Pharma Sciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Solara Active Pharma Sciences Limited (SOLARA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Solara Active Pharma Sciences Limited
About SOLARA (Solara Active Pharma Sciences Limited)
Solara Active Pharma Sciences Ltd is a prominent player in the global pharmaceutical landscape, deeply involved in the creation and delivery of essential pharmaceutical building bl...ocks. The company operates as a multifaceted entity, engaging in the meticulous manufacturing, precise production, and sophisticated processing of active pharmaceutical ingredients (APIs). With a commitment to quality and innovation, Solara plays a crucial role in the pharmaceutical value chain, ensuring the availability of high-quality APIs that underpin the production of a wide array of medications. Their extensive operations span across continents, reflecting their dedication to serving diverse healthcare needs on a global scale. Solara's reach extends beyond mere manufacturing, encompassing the entire lifecycle of pharmaceutical ingredients. They expertly formulate these APIs, skillfully blend scientific expertise with technological advancements to create products that meet stringent regulatory standards. Their commercial activities are equally robust, involving the strategic sale, import, and export of APIs, enabling them to reach key markets across India, Asia Pacific, Europe, North and South America. This global network is supported by a sophisticated merchandising, distribution, and trading infrastructure, ensuring seamless delivery and accessibility of their products to pharmaceutical manufacturers worldwide. Solara's portfolio encompasses a diverse range of APIs, targeting a wide spectrum of therapeutic areas. They supply essential ingredients for medications addressing critical conditions such as amyotrophic lateral sclerosis, as well as those used in anesthesia. Their offerings also include APIs for treatments related to hyperlipidemia, arrhythmia, asthma, hypertension, inflammation, Parkinson's disease, and retroviral infections. This breadth of therapeutic coverage highlights Solara's commitment to contributing to improved health outcomes and their dedication to supporting the development of innovative and effective pharmaceutical products across various medical disciplines.
Company Details
Key Leadership
SOLARA Share Price: Frequently Asked Questions
What is the current share price of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited (SOLARA) trades at ₹711.50 on NSE and BSE. Market cap ₹3.42K (Cr). Educational data only.
What is the P/E ratio of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited has a Bull Run score of 8/100 based on 25+ financial parameters.
Does Solara Active Pharma Sciences Limited pay dividends?
Solara Active Pharma Sciences Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited has ROE of -0.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited has debt-to-equity of 0.53.
Is Solara Active Pharma Sciences Limited a good investment?
Bull Run gives Solara Active Pharma Sciences Limited a score of 8/100. This is not investment advice — consult a SEBI-registered advisor.